Nuclear Ribonucleoprotein H1 antibodies
EstablishedHigh-titer anti-RNP without other lupus-specific antibodies is the serologic hallmark of mixed connective tissue disease.
This antibody, when found at high levels without certain other lupus antibodies, points to a specific overlap condition called mixed connective tissue disease, which combines features of several different autoimmune diseases.
Anti-ribonucleoprotein (anti-RNP) antibodies target components of the spliceosome complex within the cell nucleus, and high-titer anti-RNP without other lupus-specific antibodies is the serologic hallmark of mixed connective tissue disease (MCTD).
High-titer anti-RNP, especially in the absence of anti-Sm or anti-dsDNA, supports MCTD, a distinct overlap syndrome combining features of lupus, scleroderma, and myositis; lower-titer anti-RNP can also occur in lupus itself.
Measured via immunoassay as part of an extractable nuclear antigen (ENA) panel; the specific antibody pattern (RNP alone vs. RNP plus other ENA antibodies) helps distinguish MCTD from lupus or other overlap connective tissue diseases.
Confirmed MCTD guides monitoring for its characteristic combination of Raynaud's phenomenon, swollen hands, muscle inflammation, and pulmonary hypertension risk, which requires its own surveillance approach distinct from lupus alone.
The specific antibody combination pattern distinguishes MCTD from lupus or other overlap syndromes.
- General rheumatology reference literature on mixed connective tissue disease diagnostic criteria and anti-RNP serology.